Basmattee Boodram, BA, MPH, PhD
Community Health Sciences
Building & Room:
1603 W. Taylor St.
Infectious disease/social epidemiologist. Research focuses on the intersection of substance misuse and infectious disease among marginalized populations (e.g., people who inject illicit drugs, correctional populations, homeless).
National Institute of Drug Abuse, National Institute of Health, Contextual Risk Factors for Hepatitis C among Young Persons Who Inject Drugs, Principal Investigator
National Institute of General Medical Sciences, National Institute of Health, Computational Discovery of Effective Hepatitis C Intervention Strategies, Principal Investigator
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, The Hepatitis C Community Alliance to Test and Treat (HepCCATT) in Chicago Program, Site Principal Investigator
Echevarria D, Gutfraind A, Boodram B, Layden J, Ozik J, Page K, Cotler S, Major M, Dahari H. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine. 2019;1;37(19):2608-2616. doi: 10.1016/j.vaccine.2019.02.081.
Dahari H, Boodram B. How to eliminate hepatitis C virus among people who inject drugs in the USA. Lancet Infect Dis. 2018; 18(2):134-135.
Boodram B, Hotton A, Shekhtman L, Gutfraind A, Dahari H. High-risk geographic mobility patterns among young urban and suburban persons who inject drugs and their injection network members. J Urban Health. 2018; 95 (1): 71-82.
Mackesy-Amiti M, Boodram B, Spiller MW, Paz-Bailey G, Prachand N, Broz D. Injection-related risk behavior and engagement in outreach, intervention and prevention services across 20 U.S. cities. J Acquir Immune Defic Syndr. 2017; 75 (Supplement: 3):S316-S24.
Boodram B, Mackesy-Amiti ME, Latkin C. The role of social networks and geography on risky injection behaviors of young persons who inject drugs. Drug Alcohol Depend. 2015;154:229-35.
Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler S, Dahari H. Mathematical modeling of hepatitis C prevalence reduction with antiviral treatment scale-up in persons who inject drugs in metropolitan Chicago. PLoS One. 2015;10(8):e0135901.
Latkin CA, Davey-Rothwell MA, Knowlton AR, Alexander KA, Williams CT, Boodram B. Social network approaches to recruitment, HIV prevention, medical care, and medication adherence. J Acquir Immun Defic Syndr. 2013;63 Suppl 1:S54-8.
Boodram B, Williams CT. Collecting whole network data for human immunodeficiency virus prevention: a review of current strategies. J. AIDS HIV Res. 2013;5(4):114-26.
Boodram B, Hershow RC, Cotler SJ, Ouellet LJ. Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. Drug Alcohol Depend. 2011;119(3):166-71.
Boodram B, Golub ET, Ouellet LJ. Socio-behavioral and geographic correlates of prevalent hepatitis virus infection among young injection drug users in metropolitan Baltimore and Chicago. Drug Alcohol Depend. 2010;111(1-2):136-45.
Service to Community
Hepatitis C Elimination Task Force (2017-)
Hepatitis C Community Alliance to Test and Treat (2014-)
HIV Advisory Work Group, Illinois Department of Human Services (2009-16)
Illinois Coalition of Harm Reduction Providers (2009-16)
2018, Researcher of the Year, Clinical Sciences, Vice Chancellor of Research, University of Illinois at Chicago
2015, Health Equity and Advocacy Award, Alumni Association, University of Illinois at Chicago
2007, Dean Scholar Award, University of Illinois at Chicago
University of Illinois at Chicago, Ph.D. (Epidemiology)
Connecticut State University, M.P.H. (Public Health)
Dartmouth College, B.A. (History)
American Association for the Study of Liver Diseases
American College of Epidemiology
American Public Health Association
International AIDS Society
International Network of Social Network Analysis
- Boodram B, Hotton A. Large syringe-sharing injection networks of young persons who inject drugs. Sunbelt XXXVIII Conference, International Network for Social Network Analysis, Utrecht, Netherlands, June 26-July 1, 2018. Plenary.
- Boodram B, Dahari H, Ozik J. Modeling hepatitis C elimination among persons who inject drugs. Annual Meeting of the Models of Infectious Disease Agents Network, National Institutes of Health, Bethesda, Maryland, April 2-5, 2018.
- Boodram B, Kaufmann M, Aronsohn A, Kim K, Wolf J, Hamlish T, Johnson D, Rodriguez I. A novel hepatitis C case management and capacity building program to enhance treatment linkage and completion in a large metropolitan area. 145th Annual Meeting of the American Public Health Association, Atlanta, Georgia, November 4-8, 2017.
- Boodram B, Mackesy-Amiti M, Latkin C. Geographic mobility, social networks and syringe sharing among young persons who inject drugs from metropolitan Chicago. National HIV Prevention Conference, Atlanta, Georgia, December 6-9, 2015.
- Wilson D, Boodram B, Lalomio J. The new reality of heroin addiction in Chicago. A discussion in special session “Spatializing shattered subjects: geographies of trauma”. Annual Meeting of the Association of American Geographers, Los Angeles, California, April 9-13, 2013.
- Ouellet LJ, Boodram B, Broz D. Prescription opioid misuse and heroin initiation by young urban and suburban non-injecting heroin users in Chicago. 140th Annual Meeting of the American Public Health Association, San Francisco, California, October 27-31, 2012.
- Boodram B, Redman S, Williams CT. Strategies used to sample, recruit, and collect sociometric data for HIV prevention. 5thNational Scientific Meeting of the Social and Behavioral Sciences Research Network, Centers for AIDS Research, Atlanta, Georgia, October 7-8, 2010.
- Boodram B, Ouellet L, Golub E, Hudson S, Kapadia F, Hagan H, Garfein R. Prevalence and correlates of human immunodeficiency virus, hepatitis B and hepatitis C virus co-infection among young injection drug users: Collaborative Injection Drug Users Study III/Drug User Intervention Trial, 2002-2004. XVII International AIDS Conference, Mexico City, Mexico, August 3-8, 2008.
- Wang JH, Ke X, Boodram B, Hershow RC, Cotler S. Association of HLA-C and Class II genes and their influence on hepatitis C infection. 13th Annual International Meeting on Hepatitis C Virus & Related Viruses, Cairns, Australia, August 27-31, 2006.
- Boodram B, Hershow RC, Ouellet, LJ. Barriers to seeking medical treatment for chronic hepatitis C infection among young injecting drug users in metropolitan Chicago. 133rd Meeting of the American Public Health Association, Philadelphia, Pennsylvania, December 10-14, 2005.
Research Currently in Progress
2019-2024 1UG1DA050066 National Institute of Drug Abuse, NIH
Reducing Mortality in Illinois (ROMI), 1UG1DA050066, NIDA/NIH, PI: Basmattee Boodram, 2019-2024
ROMI is a multi-site randomized-controlled trial that seeks to examine the impact of a case management-based intervention on medication-assisted treatment uptake and improved health and criminal justice outcomes among individuals with opioid use disorder (OUD) exiting jails and prisons located in five diverse urban and rural areas Illinois that experience the high rates of OUD, overdose, and related harms. The ROMI trial will be carried out using a hub-and-spoke model for the intervention using centralized long-standing social services infrastructure at the Community Outreach Intervention Projects (COIP) at the University of Illinois at Chicago School of Public Health. ROMI will be conducted using a hybrid type-one effectiveness implementation design, which simultaneously test effectiveness and collect contextual data to inform implementation.
2019-2024 1U2CDA050098 National Institute of Drug Abuse, NIH
Methodology and Advanced Analytics Resource Center (MAARC), 1U2CDA050098, NIDA/NIH, PI: Basmattee Boodram, 2019-2024
MAARC is methodology resource center that seeks to provide advanced bi-directional data sharing, analytics and modeling capacities that will provide new scientific insights into the intersection of opioid use and the justice context that will ultimately lead to reductions in opioid misuse, overdose and death. MAARC will provide these methodological capabilities to support all clinical trials nation-wide funded under NIDA’s criminal-justice-focused JCOIN initiative. Specifically, these capabilities include advanced methods that provide best-in-class data storage, management and security with added value to these trials through products of forecasting, rapid real time assessments, and explication and exploration of trial effectiveness analysis.
2017-2022 R01DA043484 National Institute of Drug Abuse, NIH
Contextual Risk Factors for Hepatitis C among Young Persons Who Inject Drugs, R01DA043484, NIDA/NIH, PI: Basmattee Boodram, 2017-2022
A longitudinal study of 420 young persons who inject drugs and 1,156 of their drug injection network partners to examine the role of social networks, social geography, drug use social norms, and drug use stigma on (a) hepatitis C risk and drug overdose. The research project will elucidate key contextual and structural factors to inform the development of innovative strategies (e.g., network interventions) to reduce hepatitis C incidence and overdose among young people who misuse drugs.
2014-2019 1US1PS004607 Centers for Disease Control and Prevention
The Hepatitis C Community Alliance to Test and Treat in Chicago Program, 1US1PS004607 , CDC, PI: Basmattee Boodram, 2014-2019
This intervention project aims to strengthen health-care capacity to diagnose and cure hepatitis C (HCV) through implementation of a package of HCV-related services in Chicago populations with HCV-related health disparities, including individuals born between 1945 and 1965, African-Americans, and persons who inject drugs.
2002-2022 R01GM121600 National Institute of General Medical Sciences, NIH
Computational Discovery of Effective Hepatitis C Intervention Strategies, R01GM121600, NIGMS/NIH, PI: Basmattee Boodram, 2002-2022
Study aims to develop the first comprehensive, empirical data-driven agent-based computational model for a U.S.-based population of persons who inject drugs to enable policy makers to identify the most effective intervention strategies for elimination of hepatitis C in the United States, which was deemed feasible for the U.S. by 2030 by the World Health Organization.